Alex Gonzalez Bossolo, MD
Endocrinology, Diabetes & Metabolism · San Juan, PRNPI 1457606444
Payments from drug & device makers
Across 937 payments — averaging $5877.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly Export S.A. Puerto Rico Branch$3.3M
- Amgen$2M
- Novartis$93K
- Lilly USA, LLC$69K
- Eli Lilly$51K
- Pfizer$11K
- plus $17K from 20 others
Across 15 payments — averaging $5083.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly Export S.A. Puerto Rico Branch$43K
- Eli Lilly$33K
What the payments were for
- Consulting fees$2,2842%
- Speaking & faculty fees$81,35074%
- Travel & lodging$5,8485%
- Food & beverage$20,35419%
- Education$1170%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly Export S.A. Puerto Rico Branch | 71 | $3,252,810 |
| Amgen(2 entities) | 72 | $2,013,306 |
| Novartis | 24 | $93,337 |
| Lilly USA, LLC | 96 | $69,081 |
| Eli Lilly | 47 | $51,115 |
| Pfizer | 21 | $10,977 |
| Bayer | 28 | $2,540 |
| Boehringer Ingelheim | 74 | $1,986 |
| AstraZeneca | 81 | $1,937 |
| Merck | 40 | $1,631 |
| Novo Nordisk | 84 | $1,522 |
| Abbott | 84 | $1,327 |
| Medtronic | 20 | $1,226 |
| Sanofi-aventis U.S. LLC | 39 | $1,079 |
| Dexcom, Inc. | 47 | $881 |
| Bayer Puerto Rico Inc. | 39 | $849 |
| Johnson & Johnson | 26 | $751 |
| PBG Puerto Rico LLC | 15 | $284 |
| AbbVie | 11 | $252 |
| Radius Health, Inc. | 6 | $142 |
| Corcept Therapeutics | 6 | $130 |
| Mannkind Corporation | 1 | $59 |
| Boston Scientific | 1 | $47 |
| Pfizer Pharmaceuticals LLC | 2 | $39 |
| Insulet Corporation | 1 | $23 |
| Rhythm Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,507,348 in reported general payments places this provider in the 95th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
See all endocrinology, diabetes & metabolism providers in Puerto Rico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 1,309 | $1,292,482 |
| MounjaroTirzepatide | 742 | $828,912 |
| TrulicityDulaglutide | 665 | $716,003 |
| Xigduo XrDapaglifloz Propaned/Metformin | 531 | $491,296 |
| JardianceEmpagliflozin | 518 | $467,846 |
| FarxigaDapagliflozin Propanediol | 545 | $430,538 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 392 | $353,129 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 299 | $306,954 |
| SynthroidLevothyroxine Sodium | 1,585 | $117,852 |
| RybelsusSemaglutide | 89 | $89,061 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 94 | $82,296 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 75 | $67,551 |
| KerendiaFinerenone | 53 | $56,939 |
| SynjardyEmpagliflozin/Metformin Hcl | 67 | $51,008 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 62 | $49,365 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Humulin 70-30 | $69,081 | $1,583,2031,680 claims |
| Novo NordiskOzempic, Rybelsus | $1,522 | $1,381,5431,398 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr, Synjardy, Tradjenta | $1,986 | $1,311,5221,443 claims |
| AstraZenecaFarxiga | $1,937 | $430,538545 claims |
| MerckJanumet Xr, Janumet, Januvia | $1,631 | $148,747180 claims |
| AbbVieSynthroid | $252 | $117,8521,585 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $1,079 | $106,914442 claims |
| BayerKerendia | $2,540 | $56,93953 claims |
| Radius Health, Inc.Tymlos | $142 | $40,84015 claims |
| AmgenProlia | $2,013,306 | $21,00112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
Other endocrinology, diabetes & metabolism in San Juan
- Martha GomezSan Juan$3.8M
- Michelle Mangual GarciaSan Juan$743K
- Loida Gonzalez RodriguezSan Juan$246K
- Manuel Alegre-HernandezSan Juan$156K
- Monica Ortiz-RiveraSan Juan$148K
- Oscar Ruiz BermudezSan Juan$94K
- Meliza Martinez RodriguezSan Juan$80K
- Jorge de Jesus MirandaSan Juan$30K
- Zahira Lugo LopezSan Juan$29K
- Margarita Ramirez-VickSan Juan$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.